Search
MSK experts discuss risk factors, symptoms, and treatment for male breast cancer.
Sequencing advanced endometrial tumors with the MSK-IMPACT™ assay provides an effective method for detecting microsatellite instability (MSI) and germline cancer predisposition syndromes
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.
Six students have successfully defended their dissertations and will receive their PhD degrees at Commencement on May 10.
Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial Hospital Research Laboratories at MSK, which is focused on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
Computer models suggest breast cancer screening guidelines for people with mutations in the genes ATM, CHEK2, and PALB2.
MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.
Dr. Mini Kamboj, MSK’s Chief Medical Epidemiologist, explains what people with cancer and their caregivers need to know about measles and the MMR (measles, mumps, and rubella) vaccine.
The list acknowledges and celebrates healthcare leaders who envision a better future for all New Yorkers and constitute New York’s ever-expanding and constantly improving healthcare system.